Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum

被引:24
作者
Carter, J. D. [1 ]
Gerard, H. C. [2 ]
Hudson, A. P. [2 ,3 ]
机构
[1] Univ S Florida, Dept Internal Med, Div Rheumatol, Sch Med, Tampa, FL 33612 USA
[2] Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA
[3] DVA Med Ctr, Res Serv, Detroit, MI USA
关键词
D O I
10.1136/ard.2007.082842
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rarely, tumour necrosis factor (TNF)alpha antagonist therapy has been associated with de novo psoriasiform eruptions. This is unusual in that these same drugs are used to treat psoriasis. Most of these cases involve the palms and soles, yet palmoplantar pustular psoriasis represents only 1.7% of all cases of psoriasis. Keratoderma blenorrhagicum is a psoriasiform rash that occurs primarily on the palms and soles of some patients with reactive arthritis. It is grossly and histologically indistinguishable from pustular psoriasis. Chlamydia trachomatis is a common aetiological agent for reactive arthritis, and in vitro studies have shown that chlamydial replication is inversely proportional to TNF alpha levels. Three patients taking TNFa antagonists are presented who developed such lesions and who were found to be positive for C trachomatis DNA in the affected skin. It is proposed that these psoriasiform lesions may not be psoriasis, but rather keratoderma blenorrhagicum.
引用
收藏
页码:1181 / 1183
页数:3
相关论文
共 14 条
[1]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[2]  
CAMISA C, 1998, HDB PSORIASIS, P21
[3]   Reactive arthritis: Defined etiologies, emerging pathophysiology, and unresolved treatment [J].
Carter, John D. .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2006, 20 (04) :827-+
[4]   Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis:: a prospective study [J].
Flendrie, M ;
Vissers, WHPM ;
Creemers, MCW ;
de Jong, EMGJ ;
van de Kerkhof, PCM ;
van Riel, PLCM .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) :R666-R676
[5]  
Gérard HC, 1998, J RHEUMATOL, V25, P734
[6]  
Gerard HC, 2002, J RHEUMATOL, V29, P1827
[7]   Chlamydia and associated arthritis [J].
Inman, RD ;
Whittum-Hudson, JA ;
Schumacher, HR ;
Hudson, AP .
CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (04) :254-262
[8]   Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats [J].
Inman, RD ;
Chiu, B .
ARTHRITIS AND RHEUMATISM, 2006, 54 (02) :499-507
[9]   Inhibition of chlamydia trachomatis growth by human interferon-α:: mechanisms and synergistic effect with interferon-γ and tumor necrosis factor-α [J].
Ishihara, Tatsuya ;
Aga, Miho ;
Hino, Keiko ;
Ushio, Chie ;
Taniguchi, Mutsuko ;
Iwaki, Kanso ;
Ikeda, Masao ;
Kurimoto, Masashi .
BIOMEDICAL RESEARCH-TOKYO, 2005, 26 (04) :179-185
[10]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104